The effect of <i>OPRM1, ABCB1, IL1B, PTGS2, LOC 541472</i> gene polymorphism on the variability of chronic pain syndrome in patients with pancreatic cancer
Background. One of the obligate clinical manifestations of pancreatic cancer is chronic pain syndrome, which is realized in 80 % of patients with a progressive course of the disease. Studying the molecular genetic factors that influence the phenotypic realization of chronic pain syndrome in patients with pancreatic cancer is an important step towards personalizing the roadmap.Aims. To study the associative effect of single nucleotide polymorphisms (SNPs) of the OPRM1, ABCB1, IL1B, PTGS2, LOC 541472 genes on the interindividual variability of chronic pain syndrome in patients with pancreatic cancer.Materials and methods. The study included 81 patients aged 18 to 75 years with histological verification, promptly treated for prostate cancer according to the main criterion for inclusion in the study. Molecular genetic studies were performed to determine the allelic variants of rs1799971 of the OPRM1 gene, rs1045642, rs2032582, rs1128503 of the ABCB1 gene, rs1143627 of the IL1B gene, rs5275 of the PTGS2 gene, rs1800795 of the LOC gene 541472. Statistical processing of the results was carried out using the Statistica 10.0 program.Results. Carriers of the homozygous AA genotype of the OPRM1 gene prevailed among the observed patients of the Krasnoyarsk Territory with pancreatic cancer. Genotype AG IL1B showed an increase in the chances of chronic pain by 18,46 times in patients with pancreatic cancer. Carriers of the GG genotypes of the ABCB1 rs1045642 and AA genes of the ABCB1 rs2032582 gene constituted a risk group for the implementation of chronic pain in patients with pancreatic cancer.Conclusions. The study showed that the most significant in terms of increasing the chances of chronic pain in patients with pancreatic cancer are the homo- and heterozygous genotypes of the IL1B and LOC 541472 genes encoding IL-6
